Dharmik Jadvani

Researcher

University of Arkansas for Medical Sciences

unknown

1 h-index 6 pubs 9 cited

Research Areas

Cardiovascular Function and Risk Factors Meta-analysis and systematic reviews Pharmacological Effects and Toxicity Studies Dialysis and Renal Disease Management Cannabis and Cannabinoid Research Health and Medical Research Impacts Microbial infections and disease research

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dharmik Jadvani's research focuses on investigating associations between medical conditions, treatments, and patient outcomes. He has published work examining the effects of specific medications, such as Olmesartan and P2Y12 receptor inhibitors, on conditions like enteropathy and sepsis in patients with chronic kidney disease. Jadvani has also contributed to studies evaluating cardiovascular outcomes related to cannabinoid use and has conducted systematic reviews and meta-analyses on procedural modifications for pacemaker implantation post-Transcatheter Aortic Valve Replacement.

His work includes a meta-analytical evaluation of the relationship between tetra-hydro-cannabinoids and cardiovascular outcomes, specifically arrhythmia and mortality. Jadvani has also published on platelet count, platelet volume, and their relation to chronic kidney disease. His recent publications span into 2025, indicating ongoing activity in these research areas. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Nishank Jain and Lucas R. Johnson.

Metrics

h-index: 1
Publications: 6
Citations: 9

Selected Publications

Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025) DOI
Authors' Reply: Platelet Count, Platelet Volume and CKD (2024) DOI